Comment on

• Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.

  Tawbi HA, Forsyth PA, Hodi FS, Algazi AP, Hamid O, Lao CD, Moschos SJ, Atkins MB, Lewis K, Postow MA, Thomas RP, Glaspy J, Jang S, Khushalani NI, Pavlick AC, Ernstoff MS, Reardon DA, Kudchadkar R, Tarhini A, Chung C, Ritchings C, Durani P, Askelson M, Puzanov I, Margolin KA. Tawbi HA, et al. Lancet Oncol. 2021 Dec;22(12):1692-1704. doi: 10.1016/S1470-2045(21)00545-3. Epub 2021 Nov 10. Lancet Oncol. 2021. PMID: 34774225 Free PMC article. Clinical Trial.
• Nivolumab plus ipilimumab in melanoma brain metastases.

  Di Giacomo AM, Maio M. Di Giacomo AM, et al. Lancet Oncol. 2022 Feb;23(2):e53. doi: 10.1016/S1470-2045(22)00001-8. Lancet Oncol. 2022. PMID: 35114122 No abstract available.
• Nivolumab plus ipilimumab in melanoma brain metastases - Authors' reply.

  Tawbi HA, Eroglu Z, Anders CK, Margolin KA. Tawbi HA, et al. Lancet Oncol. 2022 Feb;23(2):e54. doi: 10.1016/S1470-2045(22)00033-X. Lancet Oncol. 2022. PMID: 35114123 No abstract available.